Proliferation of the carcinoma cell line H358, which exhibited a moderate activation of the HER1, HER2, and IGF-1R pathways, was weakly blocked by the HER1/2 inhibitors, Lapatinib and Gefitinib, but the IGF-1R inhibitor BMS-536924 was able to inhibit its proliferation more effectively. Here, EGFR is linked to carcinoma.